Cytonus Therapeutics

$14.4M disclosed across 5 rounds · 2018–2023

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

AG

Agenus17 shared keywordsAgenus is a biotechnology company developing cancer immunotherapies, including its lead investigational combination of botensilimab (an anti-CTLA-4 antibody) and balstilimab (a PD-1 inhibitor), known as BOT+BAL. It provides access to these investigational medicines for cancer patients through pathways such as clinical trials, Named Patient Programs, and compassionate-use programs across multiple countries.

AM

Amicus Therapeutics16 shared keywordsAmicus is a rare disease biotechnology company developing medicines for people with genetically defined conditions. It operates as a wholly owned subsidiary of BioMarin Pharmaceutical Inc.

TA

Talus Bio15 shared keywordsTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.

CY

Cytonics15 shared keywordsCytonics develops biologic therapies targeting osteoarthritis, with lead candidate CYT-108, a recombinant protease inhibitor for knee joint regeneration based on a novel pathway to restore cartilage-secreting cells. The company funds development through equity crowdfunding from individual investors rather than venture capital.

CO

Coherus Biosciences12 shared keywordsCoherus Oncology develops and commercializes immuno-oncology therapies, including the approved LOQTORZI, to treat patients with cancer. The company focuses on expanding its pipeline of clinical-stage candidates targeting the tumor microenvironment.

Companies competing with Cytonus Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.